XTX Topco Ltd cut its stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 53.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,988 shares of the company's stock after selling 14,782 shares during the period. XTX Topco Ltd's holdings in Doximity were worth $566,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. MetLife Investment Management LLC lifted its holdings in Doximity by 0.6% during the third quarter. MetLife Investment Management LLC now owns 65,064 shares of the company's stock worth $2,835,000 after buying an additional 363 shares during the period. First Horizon Advisors Inc. boosted its position in shares of Doximity by 22.5% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,094 shares of the company's stock worth $91,000 after purchasing an additional 384 shares in the last quarter. GAMMA Investing LLC grew its stake in Doximity by 40.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,439 shares of the company's stock worth $63,000 after buying an additional 412 shares during the last quarter. Van ECK Associates Corp increased its position in Doximity by 19.7% during the 2nd quarter. Van ECK Associates Corp now owns 2,590 shares of the company's stock valued at $72,000 after buying an additional 427 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. increased its holdings in shares of Doximity by 3.2% during the second quarter. Cornercap Investment Counsel Inc. now owns 17,143 shares of the company's stock valued at $479,000 after acquiring an additional 537 shares in the last quarter. Institutional investors own 87.19% of the company's stock.

NASDAQ:DOCS opened at $52.14 on Friday. The stock has a 50 day moving average price of $48.05 and a 200 day moving average price of $37.88. The stock has a market cap of $9.73 billion, a PE ratio of 59.93, a P/E/G ratio of 4.16 and a beta of 1.40. Doximity, Inc. has a one year low of $22.96 and a one year high of $61.75.

Several equities research analysts have recently commented on the stock. Evercore ISI lifted their price objective on shares of Doximity from $34.00 to $45.00 and gave the stock an "in-line" rating in a research note on Tuesday, October 8th. Raymond James reiterated an "outperform" rating and issued a $65.00 price target (up previously from $37.00) on shares of Doximity in a report on Friday, November 8th. Robert W. Baird increased their price target on Doximity from $41.00 to $45.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 17th. KeyCorp raised Doximity from a "sector weight" rating to an "overweight" rating and set a $70.00 price objective for the company in a report on Friday, November 8th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Doximity from $30.00 to $48.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Twelve research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $52.44.

View Our Latest Research Report on DOCS

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Doximity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.

While Doximity currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.